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Background: While surgical excision remains the principal management strategy
for clinical T1 renal masses (cT1RMs), the rates of noninterventional approaches
are not well known. Most single-institution and population-based series suggest
rates below 10%.
Objective: To evaluate the use of observation for newly diagnosed cT1RM patients
in academic and community-based practices across a statewide collaborative.
Design, setting, and participants: The Michigan Urological Surgery Improvement
Collaborative—Kidney mass: Identifying and Deﬁning Necessary Evaluation and
therapY (MUSIC-KIDNEY) commenced data collection in September 2017 by recording clinical, radiographic, pathologic, and short-term follow-up data for cT1RM
patients at 13 diverse practices. Patients with complete data were assessed at >90 d
after initial evaluation as to whether observation or treatment was performed.
Outcome measurements and statistical analysis: Relationships with outcomes
were analyzed using multivariable logistic regression, chi-square test, and Wilcoxon rank-sum test.
Results and limitations: Out of 965 patients, observation was employed in 48%
(n = 459), with practice-level rates ranging from 0% to 68%. Patients managed with
observation (vs treatment) were signiﬁcantly older (71.2 vs 62.8 yr, p < 0.0001) and
had smaller tumors (2.3 vs 3.4 cm, p < 0.0001). Observation was used for 53.5% of
cT1a renal masses, for 29.9% of cT1b renal masses, and for 42.5%, 53.7%, and 63.9% of
radiographically solid, Bosniak III–IV cystic, and indeterminate cT1RMs, respectively. Factors signiﬁcantly associated with observation in multivariable analysis
included lesion type (Bosniak III–IV vs solid, p = 0.017), tumor stage (cT1a vs cT1b,
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p < 0.001), and higher age (p < 0.001). A short duration of follow-up limits the
assessment of longer-term patient management.
Conclusions: Noninterventional management of cT1RMs is common across the
MUSIC-KIDNEY collaborative, with wide variability across practices. Factors associated with observation were advanced age, smaller tumor size, and cystic tumor
type. Durability of the initial decision for observation (delayed intervention vs
active surveillance vs less active surveillance) will be a focus of subsequent study.
Patient summary: The Michigan Urological Surgery Improvement Collaborative:
Kidney mass: Identifying and Deﬁning Necessary Evaluation and therapY (MUSICKIDNEY) quality improvement collaborative assessed the current utilization of
initial observation of a renal mass 7 cm across a diverse group of urology practices
and found it to be used in 48% of patients. We found that the factors predicting
observation were advanced age, smaller tumor size, and cystic tumor type.
© 2020 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1.

Introduction

The incidence of renal masses (RMs) has been on the
increase over the last 2 decades [1–3], predominately due to
the expanding utilization of cross-sectional abdominal
imaging [4]. While surgical excision remains the principal
management strategy, active surveillance (AS) has emerged
as a safe alternative in well-selected patients. Both
American Urological Association (AUA) and American
Society of Clinical Oncology (ASCO) guidelines [5,6] include
AS as a treatment option in the management of localized
RMs up to 4 cm in size (clinical stage T1a or cT1a).
For clinical T1a renal masses (cT1aRMs), the risk of
metastatic progression is low, with a meta-analysis
determining the risk to be approximately 1% over a 32mo period [7]. In addition, for all localized RMs, even those
up to 7 cm in size (cT1), the risk of death from competing
causes exceeds that of cancer-related death [8,9]. Retrospective series have indicated that surgical intervention for
clinical T1 renal masses (cT1RMs) may provide no survival
advantage in patients over the age of 75 yr, with patients
more likely to die from competing cardiovascular and other
noncancer comorbidities [10,11]. Patients who are comorbid
or elderly may, therefore, be particularly suitable for AS.
This is reflected in the rising trend of AS in patients over
70 yr of age, with the rate of AS increasing from 9.8% in
2002 to 13.6% in 2011 [12].
Understanding the current utilization of AS for cT1aRMs
or cT1RMs is difficult, with an analysis of large national
datasets such as the National Cancer Database (NCDB) and
the Surveillance, Epidemiology and End Results (SEER)Medicare database reporting AS utilization from 2.7% to 30%
[13–16]. These may not reflect current management, given
the limitations of under-reporting [17] and completeness
with geographic, ethnic, and age variation and disease site
[18].
The Michigan Urological Surgery Improvement Collaborative (MUSIC) initiated a prospective kidney mass registry
for all patients with newly presenting cT1RMs. This study
will aim to evaluate the initial management decision for
cT1RMs across a diverse range of urology practices. We

hypothesized that the use of noninterventional approaches
in academic and community-based practices for patients
diagnosed with new cT1RMs is much higher than in most
prior reports.
2.

Patients and methods

2.1.

MUSIC—Kidney mass: Identifying and Defining Necessary

Evaluation and therapY
MUSIC—Kidney mass: Identifying and Deﬁning Necessary Evaluation
and therapY (MUSIC-KIDNEY) commenced data collection in September
2017 at eight diverse MUSIC practices, with 13 practices providing data
through April 2019 [19]. Noyes et al [19] have previously reported on
MUSIC-KIDNEY inception, data collection, and practice participation. The
MUSIC coordinating center is responsible for overall administration and
management of collaborative activities. One urologist per practice serves
as the clinical champion with responsibilities that include oversight of
local data collection and leadership around local implementation of
quality improvement (QI) activities. Data abstractors recorded 122 data
points at a single time point (120 d after initial consultation), with
subsequent extraction at least 3 mo later to determine the ﬁnal
treatment assignment.

2.2.

Study population

From September 2017 to April 2019, 1248 patients have currently been
accrued who have presented to a MUSIC urologist for the ﬁrst time with a
cT1RM measuring 7 cm, as determined by imaging (computed
tomography, magnetic resonance imaging, or ultrasound). The criteria
for exclusion from analysis were Bosniak type I, II, and IIF cysts; clinical
impression of angiomyolipoma (AML); nonsuspicious lesions; and
incomplete data or follow-up (Fig. 1).

2.3.

Patient characteristics

For each patient, the following variables were extracted: patient
demographics—age, gender, Charlson Comorbidity Index (CCI), race
(white vs black vs others), insurance category (private vs public
[Medicare, Medicaid] vs uninsured vs unknown), estimated glomerular
ﬁltration rate (eGFR), and body mass index; physician characteristics—
academic versus nonacademic, location (practices in southeast Michigan
vs elsewhere), volume of cT1RMs evaluated, and utilization of renal mass
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3.1.

1248 Paents with
renal lesion ≤7 cm

Bosniak 1, 2, 2F lesion
(n = 54)
Angiomyolipoma (AML)
(n = 20)
Benign impression
(n = 8)

<120 d follow-up
(n = 193)
Missing informaon
(n = 8)

CT1RM for
Analysis
(n = 965)

Fig. 1 – Consort diagram of patients included for analysis.

biopsy (RMB); tumor characteristics—size, nephrometry score (based on
RENL characteristics of RENAL score stratiﬁed into low, intermediate, and
high complexity), and characteristics (solid vs cystic [Bosniak III–IV] vs
indeterminate, single vs multiple); and management at 120 d—
treatment (partial nephrectomy, radical nephrectomy, thermal ablation,
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Patient characteristics

When compared with those who received intervention,
patients receiving OB were older (71.2 vs 62.8 yr, p < 0.001).
Age was a significant predictor of OB in both univariate and
multivariable analysis (Table 2). Although there were
associations of insurance (private 39.2%, public 55.7%, none
53.8%, p < 0.001), eGFR (<60 ml/min 51.3%, >60 ml/min
42.2%, p = 0.014), and coexisting nonrenal tumors (56.6% vs
45.7%, p = 0.01) with OB in univariable analysis, these
associations were not maintained with multivariate analysis. CCI score and gender were not associated with the
decision to observe or intervene for a cT1RM.
For 960 patients who could be classified as those aged
<75 yr and with CCI < 2 versus those aged >75 yr or with
CCI  2, OB was utilized in 37.3% versus 59.5% (p < 0.05). For
T1a tumors, OB for patients of age <75 yr and CCI <2 versus
those of age >75 yr or CCI 2 was 43.5% versus 65.8% (p <
0.05), and for T1b tumors, it was 19.7% versus 42.1% (p <
0.05).

and other) versus observation (OB; no treatment received over study
period). The terminology of “OB” has been used in this study (instead of

3.2.

Physician and practice characteristics

AS) as the follow-up is limited to 120 d from initial consultation and
includes patients who may eventually undergo delayed intervention,
proceed to AS, or be followed with “less active” surveillance. AS was
deﬁned as a plan for reassessment with repeat imaging within 12 mo,
less active surveillance as a plan to perform repeat imaging at >12 mo,
reassurance as a plan to perform no other assessment of the RM, and
deferred treatment as any intervention for cT1RMs performed after 90 d
from initial clinical assessment.

2.4.

Statistical analysis

Clinical and demographic characteristics of patients were summarized
by the receipt of treatment using chi-square test for categorical variables
and Wilcoxon rank-sum test for continuous measures. Practice-level
variation in the utilization of OB among cT1RM patients was examined. A
multivariable logistic regression model was used to identify factors
associated with undergoing treatment (vs OB). All the analyses were

Practice-level utilization of OB ranged from 0% to 68%, with
a median of 41.7% (IQR 6.4–50) across 13 MUSIC practices
(p < 0.001; Fig. 2). Of note, seven sites contributed <20
patients each for analysis, with three of these practices
observing 0%. Provider-level differences in utilization of OB
were also noted, but the data are somewhat limited by the
small number of evaluable patients for a provider-byprovider analysis (data not shown). On univariate analysis,
physicians were more likely to observe a cT1RM if they
practiced in a nonacademic setting (52.9% vs 42.8%,
p = 0.002) and RMB was not performed (49.2% vs 39.5%,
p = 0.022); however, these associations were not maintained on multivariate analysis. Practice location was also
not associated with OB versus intervention on multivariable
analysis.

performed using SAS 9.4, and statistical signiﬁcance was indicated with
p < 0.05.

3.

Results

Among 965 patients, 506 (52%) underwent definitive
treatment within 90 d of initial consultation and OB was
employed in the remaining 459 patients (48%). Of the
patients who received intervention, the treatment received
was partial nephrectomy in 62% (n = 314), radical nephrectomy in 33% (n = 165), thermal ablation in 4.6% (n = 23), and
other in 0.8% (n = 4). Patient, physician, and tumor
characteristics for the OB and intervention cohorts are
demonstrated in Table 1. The urologist indicated that the
specific OB plan to be pursued was AS in 269 (59%), less
active surveillance in 52 (11%), and reassurance in 10 (2.2%),
and the plan was not detailed further in 128 (28%). Delayed
intervention was observed in only 3.1% of OB patients (14 of
459) who had completed at least 6 mo since initial
evaluation (median follow-up: 24.6 mo, interquartile range
[IQR] 20.1–30.4 mo).

3.3.

Tumor characteristics

Tumors that were observed were smaller (median: 2.3 cm,
IQR: 1.5–3.3 cm) than those undergoing treatment (3.4 cm,
IQR: 2.4–4.6 cm, p < 0.001; Table 1). There was decreasing
use of OB with each 1 cm increase: 77% of 0.1–1.0 cm, 66% of
1.1–2.0 cm, 49% of 2.1–3.0 cm, 34% of 3.1–4.0 cm, 33% of 4.1–
5.0 cm, 27% of 5.1–6.0 cm, and 25% of 6.1–7.0 cm. OB was
employed in 53.5% of cT1a tumors and 30% of cT1b tumors.
Factors significantly associated with OB (vs intervention) in
multivariable analysis were tumor size and radiographic
tumor type (complex cystic 53.7%, indeterminate 63.9%,
solid 42.5%, p < 0.05).
Nephrometry score was recorded for 49.3% of patients
(n = 473). Increasing tumor complexity led to lower rates of
OB (low 51.1%, intermediate 37.1%, high 34.9%, p = 0.007) in
bivariate analysis. Tumor laterality (right 47%, left 47%, p =
0.99) and number of RMs (single lesion 47.4%, multiple
lesions 46.3%, p = 0.67) were not predictors of OB. RMBs
were performed in 17% of patients with cT1RMs. Benign or
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Table 1 – Patient, physician, and tumor characteristics of observation versus treatment
Patient management (n = 965)

Age (yr), median (IQR)
Race/ethnicity, n (%)
White
African American
Others/unknown
Gender, n (%)
Male
Female
Insurance type, n (%)
Private
Public
None
Physician practice, n (%)
Academic
Nonacademic
Location, n (%)
Southeast Michigan
Elsewhere in Michigan
BMI (kg/m2)
Charlson comorbidity score, n (%)
0
1
>2
GFR (n = 863), n (%)a
>60
<60
Size (cm), median (IQR)
Tumor size/stage, n (%)
T1a
T1b
Second malignancy (nonrenal), n (%)
Yes
No
Nephrometry score (n = 473), n (%)a
Low
Intermediate
High
Multiple lesions, n (%)
Single lesion
Multiple lesions
Radiographic lesion type, n (%)
Solid
Complex cyst (Bosniak III & IV)
Indeterminate
Renal biopsy performed, n (%)
Yes
No

Observation (n = 459)

Treatment (n = 506)

Univariate p value

71.2 (61.1–78.7)

62.8 (53.3–71.0)

<0.001

371 (47.9)
62 (52.5)
26 (36.1)

404 (52.1)
56 (47.5)
46 (63.9)

0.083

248 (45.1)
211 (50.8)

302 (54.9)
204 (49.2)

0.077

186 (39.2)
264 (55.7)
7 (53.8)

289 (60.8)
210 (44.3)
6 (46.2)

<0.001

218 (42.8)
241 (52.9)

291 (57.2)
215 (47.1)

0.002

336 (46.5)
123 (50.6)
29.4 (25.6–34.3)

386 (53.5)
120 (49.4)
29.6 (26.7–35.2)

0.271

217 (44.1)
93 (48.2)
149 (53.2)

275 (55.9)
100 (51.8)
131 (46.8)

0.051

244 (42.2)
136 (51.3)
2.3 (1.5–3.3)

334 (57.8)
129 (48.7)
3.4 (2.4–4.6)

0.014

379 (53.5)
75 (29.9)

330 (46.5)
176 (70.1)

<0.001

94 (56.6)
365 (45.7)

72 (43.4)
434 (54.3)

0.010

95 (51.1)
83 (37.1)
22 (34.9)

91 (48.9)
141 (62.9)
41 (65.1)

0.007

395 (47.4)
50 (46.3)

438 (52.6)
58 (53.7)

0.826

301 (42.5)
29 (53.7)
129 (63.9)

408 (57.5)
25 (46.3)
73 (36.1)

<0.001

66 (39.5)
393 (49.2)

101 (60.5)
405 (50.8)

0.022

0.048

<0.001

BMI = body mass index; GFR = glomerular ﬁltration rate; IQR = interquartile range.
Number of patients with information available for analysis for this domain.

a

favorable benign diagnoses were made in 21% of these
patients. Of patients without malignancy at RMB, 86% were
placed on OB.
4.

Discussion

Acceptance of AS as a treatment strategy for small RMs is
growing [13]. This is, in part, based on the long-term
oncologic outcomes seen in a growing number of singleinstitutional series and evidence indicating the safety of AS
up to 10 yr in duration in select centers [7,20,21]. Rates of AS
have been reported to be in the range of 2.9–30% in prior
population-based studies [13,15,16,22], which are signifi-

cantly lower than the 46% AS rate demonstrated in this
study. We observed significant variability in the use of OB
(rates: 0–68%) within the 13 practices participating in
MUSIC-KIDNEY. Only one prior group of three academic
sites, the Delayed Intervention and Surveillance for Small
Renal Masses Registry (DISSRM), has reported a similar rate
(45%) of AS [20].
How can this discrepancy be understood? Several factors
deserve consideration: first, there is no clearly specified
definition or pathway for AS of cT1aRMs. In addition, many
patients with cT1aRMs do not need AS, as they are initially
provided reassurance that the lesion in question is not
suspicious for cancer. These patients might be better
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Table 2 – Multivariable logistical regression analysis to identify factors associated with undergoing treatment versus observation
Effect

Age
BMI
Female (vs male)
Race
African American (vs white)
Other/unknown (vs white)
Insurance
Private (vs none)
Public (vs none)
Charlson comorbidity index
1 (vs 0)
2 (vs 0)
Other malignancy
Clinical stage T1b (vs T1a)
Radiographic tumor type
Complex cyst (vs solid)
Complex cyst (vs indeterminate)
Renal mass biopsy
Multiple lesions (vs single lesion)
Academic practice (vs private)
Southeast Michigan (vs elsewhere)

OR

95% CI

p value

Lower limit

Upper limit

0.95
0.99
0.84

0.94
0.97
0.62

0.96
1.01
1.12

<0.0001
0.350
0.227

0.78
1.07

0.49
0.60

1.23
1.91

0.278
0.808

2.32
2.05

0.70
0.62

7.63
6.82

0.168
0.240

1.07
0.89
0.79
2.90

0.73
0.56
0.45
2.06

1.57
1.44
1.37
4.07

0.726
0.644
0.392
<0.0001

0.47
0.98
1.36
0.97
1.27
1.11

0.25
0.49
0.93
0.61
0.87
0.72

0.88
1.94
2.00
1.54
1.86
1.71

0.017
0.946
0.112
0.908
0.219
0.645

BMI = body mass index; CI = conﬁdence interval; OR = odds ratio.
Tumor complexity was not included as a variable due to incomplete information of 489 patients.

assigned a term such as “reassurance” or “OB,” which is
more aligned with the clinical intent to observe a benign
lesion, than the term “watchful waiting” in which the
clinical impression is that the patient will not benefit from
localized treatment for the presumed cancer [23]. Other
lesions that are indeterminate or are too small to
characterize are also commonly observed but would not
appear in cancer registries. For these reasons, the actual
rates of OB (vs AS) may differ dramatically. Applying the
criteria used to identify patients in the SEER/Medicare
registry to our series of patients, only 4.4% of patients would
be found to be on AS. Similarly, for the NCDB, the proportion
on AS would be 6.8%. Our methodology, therefore, allows for
an explanation of these seemingly disparate results.
Our data are not the first to indicate a high rate of OB for
small RMs. Pierorazio et al [20] in 2015 reported the results
of the DISSRM registry, where 45% of patients underwent AS
after initial presentation. They had postulated that their
higher observed rates of AS were attributed to (1) patients
being seen in tertiary referral centers where patients with
complex presentations are evaluated; (2) an inherent
propensity to select AS (for patients and physicians alike)
when a surveillance protocol exists; and (3) a small
proportion of patients undergoing primary intervention
either refusing or missing enrollment, while very few
patients choosing AS refusing enrollment to DISSRM. A
recent presentation by Menon et al [24] described the use of
“universal” surveillance for RMs as well, where failure to
remain on protocol was seen only in 1% of patients.
Our data provide further insights into noninterventional
strategies for cT1RMs, suggesting alternative explanations
for the high rates of noninterventional approaches observed
in 13 practices contributing data to MUSIC-KIDNEY. First, it
does not appear that OB rates were high only at tertiary

referral centers, as almost half of the patients within the
MUSIC-KIDNEY collaborative were managed at community
practices. Second, no MUSIC-led protocol for the management of T1RMs exists at present, and there has not yet been
a QI effort targeting increased (or decreased) use of OB in
Michigan. Third, within MUSIC-KIDNEY, there is no concern
about selection bias for enrollment, as all patients with
cT1RMs at participating sites are included. Additionally, the
MUSIC registry includes all cT1RMs (both cT1a and cT1b),
while most of the previous studies examined only cT1a
tumors, making our findings even more striking. In our
study, OB was employed in 53.5% of patients with cT1a
tumors and 30% of patients with cT1b tumors. It is possible
that the inclusion of all RMs presenting to a MUSIC-KIDNEY
urologist might have allowed for more nonsuspicious
lesions to be included in our dataset. We, however, excluded
simple and minimally complex cysts (Bosniak I, II, IIF),
AMLs, and clinician-determined nonsuspicious lesions at
the outset. Indeterminate lesions were included, and these
patients were more likely to undergo OB (63.9%) than those
with Bosniak III–IV cysts (53.7%) or solid tumors (42.5%);
however, when the indeterminate lesions are excluded, OB
was still employed in 43% of all suspicious cT1 lesions. The
higher rate of OB seen in case of suspicious complex cysts is
not surprising. It has been shown that they exhibit low
cancer mortality risk [25] and 50% likelihood of a Bosniak III
cyst having benign pathology outcome at surgical intervention [26].
There are several notable findings from our analysis
regarding the utilization of OB within our collaborative. The
patient factor most strongly associated with OB was older
age, as has been shown in several other studies [14,15]. Of
note, there was no association between medical comorbidity or baseline renal function and choice of OB, despite prior
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Fig. 2 – Practice variation of observation of cT1RM. The box table demonstrates the number of patients at each practice undergoing observation versus
treatment. cT1RM = clinical T1 renal mass.

reports indicating that those with comorbid illnesses have
competing mortality risks [9,11]. This might discriminate
itself with longer follow-up, where more comorbid patients
adopt a “watchful waiting” strategy and younger, healthier
patients adopt AS with some proportion undergoing
delayed intervention. This hypothesis will be tested when
greater length of follow-up is available in the MUSICKIDNEY cohort.
Variability was seen in the utilization of OB among
practices; however, no obvious factors seemed to attribute
to this variability. A prior NCDB study [15] had reported
academic setting being a factor in increased OB; however,
this was not seen in our study, with no difference observed
on multivariate analysis. Owing to a small number of cases
(<20) in seven practices, further analysis per practice could
not be performed at this time. After OB has been selected
initially, each patient is managed with AS, “less active”
surveillance, or reassurance. These differ in terms of
approach/intent and protocol. Examining variation in the
selection of each of these approaches, and standardizing
these approaches, will be a QI goal for the collaborative in
the near term. RMB was performed in only 14% of patients
undergoing OB. At present, the AUA identifies RMB as an
option for the newly presenting RMs [5]. The European
Association of Urology (EAU) recommends RMB in patients
in whom OB is pursued (grade C evidence) [27]. While there
has been increasing zest for RMB in the urologic literature
and a number of centers around the world are recommending RMB [28], this does not hold true in our collaborative.
The DISSRM registry was also criticized for a low RMB rate,
but we would argue that more RMBs do not necessarily lead
to less intervention overall, particularly when performed on
patients inclined toward OB. In MUSIC-KIDNEY practices,
the likelihood of intervention was almost 9% higher in
patients undergoing RMB than in those in whom no RMB

had been performed, contrary to prior reports [29]. This
might be a result of patients receiving a certain diagnosis of
malignancy at RMB, leading to the patient and/or loved ones
feeling a greater urgency for intervention. Further investigation of the factors leading to RMB and its utilization will
be the focus of further studies.
The most notable limitation of the present study is the
short follow-up. The patients within this cohort classified as
being managed initially with OB will be categorized, with
longer follow-up, into four groups: reassurance (for
nonmalignant lesions), watchful waiting (or less active
surveillance), AS, and delayed intervention. The DISSRM
registry has reported that crossover to delayed intervention
was limited to 9% [20]. The MUSIC-KIDNEY registry
continues to collect data on all patients at least yearly
after enrollment, allowing for the opportunity to further
assess outcomes with time. It is also important to recognize
that this study had seven practices, with each contributing
<20 patients. As a result, some patterns observed may be
biased by the higher-volume centers.
5.

Conclusions

The MUSIC-KIDNEY statewide QI collaborative provides an
opportunity to assess the factors that influence the
management of cT1RMs across a range of practice types.
OB is employed widely across our state, with 48% of renal
tumors 7 cm being managed initially without definitive
intervention. OB is more common for tumors <3 cm, age
>75 yr, and indeterminate renal lesions, but is also
performed selectively in those not meeting these criteria.
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